-
Innovation Ranking
NewInnovation Ranking – Cancer Genetics Inc
Vyant Bio Inc (Vyant Bio) is a pharmaceutical company that offers diagnostic products and services enabling precision medicine in the field of oncology. It offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. The company's oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies and cancer centers. CGI also provides clinical services such as expanding DX, test menu, complete program and summation report. It offers a range of pharmacogenomics testing services for clinical...
-
Innovation Ranking
NewInnovation Ranking – Myriad Genetics Inc
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, engaged in the discovery and commercialization of molecular diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions, and corresponding proteins to assess a person’s risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient’s likelihood of responding to a particular drug. Myriad markets its...
-
Product Insights
NewNet Present Value Model: Applied Genetic Technologies Corp’s Laruparetigene Zovaparvovec
Empower your strategies with our Net Present Value Model: Applied Genetic Technologies Corp's Laruparetigene Zovaparvovec report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Fulgent Genetics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Fulgent Genetics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Myriad Genetics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Myriad Genetics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval Analysis for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
Overview How likely is it that the drugs in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview Familial hypercholesterolemia (FH)...
-
Product Insights
NewLikelihood of Approval Analysis for Low-Grade Glioma
Overview How likely is it that the drugs in Low-Grade Glioma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Low-Grade Glioma Overview Low-grade gliomas are benign grade 1 and grade 2...
-
Product Insights
NewLikelihood of Approval Analysis for Inherited Metabolic Disorders
Overview How likely is it that the drugs in Inherited Metabolic Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inherited Metabolic Disorders Overview Genetic defects causing metabolic problems are referred...
-
Product Insights
NewLikelihood of Approval Analysis for Neurofibromatoses
Overview How likely is it that the drugs in Neurofibromatoses will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neurofibromatoses Overview Neurofibromatosis (NF) is a term for a group of genetic disorders...
-
Product Insights
NewLikelihood of Approval Analysis for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Overview How likely is it that the drugs in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)...